Zelboraf UK launch but reimbursement decision some time off
This article was originally published in Scrip
Roche has launched its melanoma drug Zelboraf (vemurafenib) in the UK. It has been priced at £7,000 for a four-week course. However, a reimbursement decision from NICE, the health technology appraisal institute for England and Wales, is not expected until October, the company told Scrip.